癌症是一种多方面、复杂的疾病，其特征为细胞不受控制的增殖速度并具有扩散和侵袭其他器官的能力。新兴数据表明，在癌症进程中涉及到多条通路和分子靶点。其中，Wnt信号通路在癌症的发生和进展中具有重要作用。Dishevelled（DVL）在Wnt通路的规范和非规范分支点起作用。DVL不仅在细胞质中起到抑制β-连环蛋白破坏复合体的作用，还被转运到细胞核中影响靶基因的转录。现有数据显示，DVL在各种癌症的细胞和临床标本中的表达水平增加，提示其可能具有致癌作用。DVL促进细胞侵袭、迁移、细胞周期、存活、增殖、3D球状体形成、干细胞特性和上皮间质转化（EMT），并抑制细胞凋亡。DVL的高表达水平与受癌症影响患者的临床病理特征相关，包括淋巴结转移、肿瘤分级、组织学类型和年龄。此外，DVL的高水平可能作为癌症的有希望的诊断和预后生物标志物，并可能作为癌症对甲氨蝶呤、紫杉醇和5-氟尿嘧啶等药物化疗的介质。本研究旨在探讨DVL在癌症发病机制中的潜在分子机制，以及探索其在癌症诊断、预后以及化疗中的重要性。版权所有 © 2023 Elsevier GmbH。保留所有权利。

Cancer is a multifaceted and complex disorder characterized by uncontrolled rates of cell proliferation and its ability to spread and attack other organs. Emerging data indicated several pathways and molecular targets are engaged in cancer progression. Among them, the Wnt signaling pathway was shown to have a crucial role in cancer onset and progression. Dishevelled (DVL) acts in a branch point of canonical and non-canonical Wnt pathway. DVL not only acts in the cytoplasm to inactivate the destruction complex of β-catenin but is also transported into the nucleus to affect the transcription of target genes. Available data revealed that the expression levels of DVL increased in cell and clinical specimens of various cancers, proposing that it may have an oncogenic role. DVL promoted cell invasion, migration, cell cycle, survival, proliferation, 3D-spheroid formation, stemness, and epithelial mesenchymal transition (EMT) and it suppressed cell apoptosis. The higher levels of DVL is associated with the clinicopathological characteristic of cancer-affected patients, including lymph node metastasis, tumor grade, histological type, and age. In addition, the higher levels of DVL could be a promising diagnostic and prognostic biomarker in cancer as well as it could be a mediator in cancer chemoresistance to Methotrexate, paclitaxel, and 5-fluorouracil. This study aimed to investigate the underlying molecular mechanism of DVL in cancer pathogenesis as well as to explore its importance in cancer diagnosis and prognosis as well as its role as a mediator in cancer chemotherapy.Copyright © 2023 Elsevier GmbH. All rights reserved.